90332-82-4 Usage
Description
(D(CH2)(5/1),D-TYR(ET)2,VAL4,ARG8,DES-GLY9)-VASOPRESSIN is a synthetic peptide hormone derived from the natural hormone vasopressin. It is composed of a specific sequence of amino acids, including D-TYR(ET)2, VAL4, ARG8, and DES-GLY9. This synthetic form has been modified to enhance its stability and potency, making it a stronger and longer-lasting version of the natural hormone. It plays a crucial role in regulating the body's water balance, blood pressure, and kidney function, and possesses vasoconstrictive properties that cause blood vessels to narrow.
Uses
Used in Medical Applications:
(D(CH2)(5/1),D-TYR(ET)2,VAL4,ARG8,DES-GLY9)-VASOPRESSIN is used as a vasoconstrictor for treating low blood pressure or stopping bleeding. Its ability to narrow blood vessels makes it a valuable tool in medical settings where controlling blood flow is essential.
Used in Nephrology:
In the field of nephrology, (D(CH2)(5/1),D-TYR(ET)2,VAL4,ARG8,DES-GLY9)-VASOPRESSIN is used as a diuretic agent to regulate kidney function and manage water balance in the body. Its impact on the body's water balance and blood pressure makes it a useful treatment for various kidney-related conditions.
Used in Emergency Medicine:
(D(CH2)(5/1),D-TYR(ET)2,VAL4,ARG8,DES-GLY9)-VASOPRESSIN is used as an emergency medicine to manage conditions that involve significant blood loss or shock. Its vasoconstrictive properties help stabilize patients by increasing blood pressure and reducing bleeding.
Used in Cardiology:
In cardiology, (D(CH2)(5/1),D-TYR(ET)2,VAL4,ARG8,DES-GLY9)-VASOPRESSIN is used as a therapeutic agent for managing heart conditions that involve low blood pressure or irregular heart rhythms. Its ability to regulate blood pressure and improve cardiovascular function makes it a valuable asset in treating certain cardiac conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 90332-82-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,3,3 and 2 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 90332-82:
(7*9)+(6*0)+(5*3)+(4*3)+(3*2)+(2*8)+(1*2)=114
114 % 10 = 4
So 90332-82-4 is a valid CAS Registry Number.
InChI:InChI=1/C51H74N12O10S2/c1-4-73-33-19-17-32(18-20-33)26-35-44(67)59-36(25-31-13-7-5-8-14-31)46(69)62-42(30(2)3)48(71)60-37(27-40(52)64)45(68)61-38(29-74-75-51(28-41(65)57-35)21-9-6-10-22-51)49(72)63-24-12-16-39(63)47(70)58-34(43(53)66)15-11-23-56-50(54)55/h5,7-8,13-14,17-20,30,34-39,42H,4,6,9-12,15-16,21-29H2,1-3H3,(H2,52,64)(H2,53,66)(H,57,65)(H,58,70)(H,59,67)(H,60,71)(H,61,68)(H,62,69)(H4,54,55,56)/t34-,35+,36-,37-,38-,39-,42-/m0/s1
90332-82-4Relevant articles and documents
C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors
Manning,Misicka,Olma,Klis,Bankowski,Nawrocka,Kruszynski,Kolodziejczyk,Cheng,Seto,Wo,Sawyer
, p. 2245 - 2252 (2007/10/02)
We report the solid-phase synthesis of 12 desGly and 12 desGly(NH2) analogues of arginine-vasopressin (AVP), two highly selective antidiuretic (V2) agonists, four vasopressor (V1) antagonists, and five V2/V1 antagonists. The parent AVP agonists are (1) AVP, (2) 1-deamino[8-D-arginine]vasopressin (dDAVP), and (3) its 4-valine analogue, dVDAVP. The parent V1 antagonists are (4) [1-(β-mercapto-β,β-pentamethylenepropionic acid)]arginine-vasopressin (d(CH2)5AVP), (5) d(CH2)5VDAVP, (6) [1-deaminopenicillamine,4-valine,8-D-arginine]vasopressin (dPVDAVP), and (7) d(CH2)5[Tyr(Me)]AVP. The parent V2/V1 antagonists are (8) d(CH2)5[D-Phe2,Ile4]AVP, (9) d(CH2)5[D-Phe2]VAVP, (10) d(CH2)5[D-Tyr(Et)2]VAVP, (11) d(CH2)5[Tyr(Et2]VAVP, and (12) d(CH2)5[D-Ile2,Ile4]AVP. All 24 analogues were tested for agonistic and antagonistic activities in in vivo rat vasopressor and rat antidiuretic assays. The desGly and desGly(NH2) analogues of 1-3 are either weak partial agonists or weak antagonists of the V1 responses to AVP. Except for desGly(NH2)AVP, which is a weak V2 agonist, the remaining desGly and desGly(NH2) analogues of 1-3 exhibit substantial V2 agonism and are thus highly selective V2 agonists. With antidiuretic activity of 321 units/mg, a resynthesized desGly(NH2)dVDAVP is equipotent with AVP as a V2 agonist. Thus our previously stated conclusion about the need for C-terminal CONH2 for V2 agonism is no longer valid. The four pairs of desGly/desGly(NH2) analogues of the V1 antagonists (4-7) all retained varying degrees of V1 antagonism and some exhibited striking enhancements in anti-V1/V2 selectivity. Thus the desGly/desGly(NH2) analogues of d(CH2)5Tyr(Me)AVP are highly potent V1 antagonists/weak V2 antagonists with anti-V1/V2 selectivities of 200 and 1200, respectively. The four pairs of desGly/desGly(NH2) analogues of the V2/V1 antagonists (8-11) exhibited enhancements, full retention, or slight diminishment of both V1 and V2 antagonism, with the desGly analogue being usually the more potent of each pair. The desGly and desGly(NH2) analogues of d(CH2)5[D-Ile2,Ile4]AVP (12) exhibited anti-V2/V1 selectivities of 46 and about 440, respectively. These are the most selective V2 antagonists reported to date. Many of these analogues could serve as useful pharmacological tools in studies on the roles of AVP in normal and pathophysiological circumstances.
